BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35477477)

  • 21. Autophagy Regulatory Genes MET and RIPK2 Play a Prognostic Role in Pancreatic Ductal Adenocarcinoma: A Bioinformatic Analysis Based on GEO and TCGA.
    Li X; Li Z; Zhu H; Yu X
    Biomed Res Int; 2020; 2020():8537381. PubMed ID: 33204717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].
    Konno R
    Hum Cell; 2001 Dec; 14(4):261-6. PubMed ID: 11925926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of metastasis and prognosis-associated genes for serous ovarian cancer.
    Yang Y; Qi S; Shi C; Han X; Yu J; Zhang L; Qin S; Gao Y
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
    Kim YW; Kim EY; Jeon D; Liu JL; Kim HS; Choi JW; Ahn WS
    Drug Des Devel Ther; 2014; 8():293-314. PubMed ID: 24591819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
    Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
    BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RIPK2 promotes the progression of colon cancer by regulating BIRC3-mediated ubiquitination of IKBKG.
    Zhang Z; Pan Y; Zhao Y; Ren M; Li Y; Lu G; He S
    Exp Cell Res; 2023 Aug; 429(1):113644. PubMed ID: 37211186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
    Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
    Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
    Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
    Front Immunol; 2022; 13():923194. PubMed ID: 35935940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 33. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
    Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT
    Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
    Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
    BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
    d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
    PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Knockdown of receptor-interacting serine/threonine protein kinase-2 (RIPK2) affects EMT-associated gene expression in human hepatoma cells.
    Wu S; Kanda T; Nakamoto S; Imazeki F; Yokosuka O
    Anticancer Res; 2012 Sep; 32(9):3775-83. PubMed ID: 22993319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.
    Huang GS; Brouwer-Visser J; Ramirez MJ; Kim CH; Hebert TM; Lin J; Arias-Pulido H; Qualls CR; Prossnitz ER; Goldberg GL; Smith HO; Horwitz SB
    Clin Cancer Res; 2010 Jun; 16(11):2999-3010. PubMed ID: 20404007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
    Yamaguchi N; Mimoto R; Yanaihara N; Imawari Y; Hirooka S; Okamoto A; Yoshida K
    Tumour Biol; 2015 Aug; 36(8):5913-23. PubMed ID: 25712377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential expression of immune related genes in high-grade ovarian serous carcinoma.
    Siamakpour-Reihani S; Cobb LP; Jiang C; Zhang D; Previs RA; Owzar K; Nixon AB; Alvarez Secord A
    Gynecol Oncol; 2020 Mar; 156(3):662-668. PubMed ID: 31918995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of STAT3 reverses Taxol-resistance in ovarian cancer by down-regulating G6PD expression in vitro.
    Sheng H; Feng Q; Quan Q; Sheng X; Zhang P
    Biochem Biophys Res Commun; 2022 Aug; 617(Pt 2):62-68. PubMed ID: 35689843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.